Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David H Peng

Showing results (41-50 of 54) with videos related to

Pageof 6
Sort By:
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Cancer Cell|December 15, 2023
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinomaYunfan Sun, Pin Wu, Zefan Zhang, et al.
Cancer Research|September 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic CancerYongkun Wei, Minghui Liu, Er-Yen Yen, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinomaKathleen M McAndrews, Krishnan K Mahadevan, Bingrui Li, et al.
Nature Communications|July 3, 2021
Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinomaYun-Fan Sun, Liang Wu, Shi-Ping Liu, et al.
Nature Cancer|June 18, 2021
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancerJiehui Deng, Aatish Thennavan, Igor Dolgalev, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.
Pageof 6

Showing results (41-50 of 54) with videos related to

Sort By:
Pageof 6
NPJ Breast Cancer|December 3, 2025
CDK2 inhibition enhances CDK4/6 inhibitor antitumor activity in comprehensive breast cancer PDX model screenNealia C House, Maxine M Chen, Sima Khazaei, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 19, 2020
STING Pathway Expression Identifies NSCLC With an Immune-Responsive PhenotypeCarminia M Della Corte, Triparna Sen, Carl M Gay, et al.
Cancer Cell|December 15, 2023
Integrated multi-omics profiling to dissect the spatiotemporal evolution of metastatic hepatocellular carcinomaYunfan Sun, Pin Wu, Zefan Zhang, et al.
Cancer Research|September 18, 2025
KRAS Inhibition Activates an Actionable CD24 "Do Not Eat Me" Signal in Pancreatic CancerYongkun Wei, Minghui Liu, Er-Yen Yen, et al.
Biorxiv : the Preprint Server for Biology|May 3, 2023
<i>In vivo</i> metabolomics identifies CD38 as an emergent vulnerability in <i>LKB1</i> -mutant lung cancerJiehui Deng, David H Peng, David Fenyo, et al.
Biorxiv : the Preprint Server for Biology|August 12, 2025
CDK8 remodels the tumor microenvironment to resist the therapeutic efficacy of targeted KRAS <sup>G12D</sup> inhibition in pancreatic ductal adenocarcinomaKathleen M McAndrews, Krishnan K Mahadevan, Bingrui Li, et al.
Nature Communications|July 3, 2021
Dissecting spatial heterogeneity and the immune-evasion mechanism of CTCs by single-cell RNA-seq in hepatocellular carcinomaYun-Fan Sun, Liang Wu, Shi-Ping Liu, et al.
Nature Cancer|June 18, 2021
ULK1 inhibition overcomes compromised antigen presentation and restores antitumor immunity in LKB1 mutant lung cancerJiehui Deng, Aatish Thennavan, Igor Dolgalev, et al.
Nature Cancer|August 5, 2024
Co-targeting SOS1 enhances the antitumor effects of KRAS<sup>G12C</sup> inhibitors by addressing intrinsic and acquired resistanceVenu Thatikonda, Hengyu Lyu, Sabine Jurado, et al.
Science Translational Medicine|January 24, 2020
PI4KIIIβ is a therapeutic target in chromosome 1q-amplified lung adenocarcinomaXiaochao Tan, Priyam Banerjee, Edward A Pham, et al.
Pageof 6